Neoadjuvant Triplet Immune Checkpoint Blockade in Newly Diagnosed Glioblastoma

Scientists presented a case of newly diagnosed IDH-wild-type, MGMT promoter unmethylated glioblastoma, treated with a single dose of neoadjuvant triplet immunotherapy followed by maximal safe resection 12 days later.